Top Markets
Coin of the day
Molecular Pharmacology (USA), Ltd. Molecular Pharmacology (USA), Ltd.

Molecular Pharmacology (USA), Ltd.

MLPH
株式のランク #39112
As a development-stage company, Molecular Pharmacology (USA) Limited (MLPH) is... As a development-stage company, Molecular Pharmacology (USA) Limited (MLPH) is dedicated to the creation and market introduction of solutions for pain and inflammation, with a primary focus on the Australian and United States markets. Through its subsidiary, Molecular Pharmacology Pty. Ltd., it is advancing an analgesic and anti-inflammatory molecule called Tripeptofen, designed to alleviate common daily pain. These products are offered in diverse dosage forms, formulations, and packaging options to suit various needs. MLPH's marketing strategy involves leveraging pharmaceutical distributors and forging collaborative partnerships with companies in the United States and Europe. Additionally, the company maintains an agreement with Dermatology Development Corporation to jointly develop and market a suite of therapeutic, cosmetic, and cosmeceutical items derived from the ThermaLIFE product line and its core active component. Headquartered in Perth, Australia, Molecular Pharmacology (USA) Limited operates as a subsidiary of PharmaNet Group Limited.
株価
$0.0322
最終同期: 2026-08-11
時価総額
$643.71K
変化(1日)
0.00%
変化(1年)
544.00%
AU
取引 Molecular Pharmacology (USA), Ltd. (MLPH)

カテゴリー

Molecular Pharmacology (USA), Ltd.(MLPH)のP/B比率
2026 時点のP/B比率 TTM: 0
Molecular Pharmacology (USA), Ltd. の最新の財務報告および株価によると、現在のP/B比率(TTM)は 0 です。2026 年末時点でのP/B比率は 0 でした。
Molecular Pharmacology (USA), Ltd. の P/B 比率の履歴(2026 ~ 2026)
各年末時点のP/B比率
P/B比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/B比率
企業 P/B比率 P/B比率の差
6.2613 -
US
6.3483 -
NL
- -
CH
- -
KR
3.634 -
BE